Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and-independent mechanisms

Cell Death and Disease

Volumn 4, Issue 7, 2013, Pages

  Ali, A ^a,b,c   Bluteau, O ^a,b,c   Messaoudi, K ^a,b,c   Palazzo, A ^a,b,c   Boukour, S ^a,b,c   Lordier, L ^a,b,c   Lecluse, Y ^d   Rameau, P ^d   Kraus Berthier, L ^e   Jacquet Bescond, A ^e   Lelievre H ^e   Depil, S ^e   Dessen, P ^d   Solary, E ^a,b,c   Raslova, H ^a,b,c   Vainchenker, W ^a,b,c   Plo, I ^a,b,c   Debili, N ^a,b,c  

^a Institut National de la Santé et de la Reserche Médicale   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSERM   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e IRIS Institut de Recherches Internationales Servier   (France)

Author keywords

Apoptosis; HDACi; Megakaryocytes

Indexed keywords

ABEXINOSTAT; ATM PROTEIN; HISTONE DEACETYLASE; HISTONE H2AX; PROTEIN BAX; PROTEIN P21; PROTEIN P53; RAD51 PROTEIN; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; COLONY FORMING UNIT; CONTROLLED STUDY; DNA STRAND BREAKAGE; DRUG MECHANISM; ENZYME INHIBITION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MEGAKARYOCYTE; MEGAKARYOPOIESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THROMBOCYTOPENIA;

ACETYLATION; BENZOFURANS; CELL GROWTH PROCESSES; DNA REPAIR; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84881059186     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.260     Document Type: Article

References (50)

1. Boyes J, Byfield P, Nakatani Y, Ogryzko V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 1998; 396: 594-598.
2. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90: 595-606.
3. Janke C, Bulinski JC. Post-translational regulation of the microtubule cytoskeleton: mechanisms and functions. Nat Rev Mol Cell Biol 2011; 12: 773-786.
4. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38-51.
5. Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007; 26: 5310-5318.
6. Yang XJ, Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell 2008; 31: 449-461.
7. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009; 325: 834-840.
8. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008; 9: 206-218.
9. Bird AW, Yu DY, Pray-Grant MG, Qiu Q, Harmon KE, Megee PC et al. Acetylation of histone H4 by Esa1 is required for DNA double-strand break repair. Nature 2002; 419: 411-415.
10. Peterson CL, Cote J. Cellular machineries for chromosomal DNA repair. Genes Dev 2004; 18: 602-616.
11. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391: 815-818.
12. Guidez F, Howell L, Isalan M, Cebrat M, Alani RM, Ivins S et al. Histone acetyltransferase activity of p300 is required for transcriptional repression by the promyelocytic leukemia zinc finger protein. Mol Cell Biol 2005; 25: 5552-5566.
13. Marks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 2009; 107: 600-608.
14. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27: 5459-5468.
15. Duvic M, Vu J. Vorinostat in cutaneous T-cell lymphoma. Drugs Today (Barc) 2007; 43: 585-599.
16. Martinez-Iglesias O, Ruiz-Llorente L, Sánchez-Martínez R, García L, Zambrano A, Aranda A. Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clin Transl Oncol 2008; 10: 395-398.
17. Marson CM. Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer. Anticancer Agents Med Chem 2009; 9: 661-692.
18. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109: 31-39.
19. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009; 27: 2052-2058.
20. Galli M, Salmoiraghi S, Golay J, Gozzini A, Crippa C, Pescosta N et al. A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann Hematol 2010; 89: 185-190.
21. Kavanaugh SM, White LA, Kolesar JM. Vorinostat: a novel therapy for the treatment of cutaneous T-cell lymphoma. Am J Health Syst Pharm 2010; 67: 793-797.
22. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009; 27: 5410-5417.
23. Wilting RH, Yanover E, Heideman MR, Jacobs H, Horner J, van der Torre J et al. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J 2010; 29: 2586-2597.
24. Bishton MJ, Harrison SJ, Martin BP, McLaughlin N, James C, Josefsson EC et al. Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood 2011; 117: 3658-3668.
25. Iancu-Rubin C, Gajzer D, Mosoyan G, Feller F, Mascarenhas J, Hoffman R. Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation. Exp Hematol 2012; 40: 564-574.
26. Matsuoka H, Unami A, Fujimura T, Noto T, Takata Y, Yoshizawa K et al. Mechanisms of HDAC inhibitor-induced thrombocytopenia. Eur J Pharmacol 2007; 571: 88-96.
27. Evans A, Ai W, Balasubramanian S, Sirisawad M, Mani C, Guerra M et al. Phase 1 analysis of the safety and pharmacodynamics of the novel broad spectrum HDACi PCI-24781 in relapsed and refractory lymphoma. Blood 2009; 114, [abstract: 2726].
28. Besancenot R, Chaligné R, Tonetti C, Pasquier F, Marty C, Lé cluse Y et al. A senescencelike cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferation. PLoS Biol 2010; 8, pii: e1000476.
29. Wang Y, Fiskus W, Chong DG, Buckley KM, Natarajan K, Rao R et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 2009; 114: 5024-5033.
30. Jeanpierre S, Nicolini FE, Kaniewski B, Dumontet C, Rimokh R, Puisieux A et al. BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signaling. Blood 2008; 112: 3154-3163.
31. Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM, Buggy JJ. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci USA 2007; 104: 19482-19487.
32. Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM. et al. Vorinostat in solid and hematologic malignancies. J Hematol Oncol 2009; 2: 31.
33. Guerini V, Barbui V, Spinelli O, Salvi A, Dellacasa C, Carobbio A et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 2008; 22: 740-747.
34. Boyault C, Sadoul K, Pabion M, Khochbin S. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene 2007; 26: 5468-5476.
35. Kapuria V, Levitzki A, Bornmann WG, Maxwell D, Priebe W, Sorenson RJ. et al. A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination. Cell Signal 2011; 23: 2076-2085.
36. Lee JH, Choy ML, Ngo L, Foster SS, Marks PA. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA 2010; 107: 14639-14644.
37. Miller KM, Tjeertes JV, Coates J, Legube G, Polo SE, Britton S et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol 2010; 17: 1144-1151.
38. Robert T, Vanoli F, Chiolo I, Shubassi G, Bernstein KA, Rothstein R. et al. HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature 2011; 471: 74-79.
39. Vyas P, Ault K, Jackson CW, Orkin SH, Shivdasani RA. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood 1999; 93: 2867-2875.
40. Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, Jackson CW, Hunt P, Saris CJ et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell 1995; 81: 695-704.
41. Lamonica JM, Vakoc CR, Blobel GA. Acetylation of GATA-1 is required for chromatin occupancy. Blood 2006; 108: 3736-3738.
42. Hong W, Nakazawa M, Chen YY, Kori R, Vakoc CR, Rakowski C. et al. FOG-1 recruits the NuRD repressor complex to mediate transcriptional repression by GATA-1. EMBO J 2005; 24: 2367-2378.
43. Miccio A, Wang Y, Hong W, Gregory GD, Wang H, Yu X et al. NuRD mediates activating and repressive functions of GATA-1 and FOG-1 during blood development. EMBO J 2010; 29: 442-456.
44. Valenzuela-Fernandez A, Cabrero JR, Serrador JM, Sanchez-Madrid F. HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol 2008; 18: 291-297.
45. Zhang Y, Kwon S, Yamaguchi T, Cubizolles F, Rousseaux S, Kneissel M et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 2008; 28: 1688-1701.
46. Gilles L, Bluteau D, Boukour S, Chang Y, Zhang Y, Robert T et al. MAL/SRF complex is involved in platelet formation and megakaryocyte migration by regulating MYL9 (MLC2) and MMP9. Blood 2009; 114: 4221-4232.
47. Debili N, Louache F, Vainchenker W. Isolation and culture of megakaryocyte precursors. Methods Mol Biol 2004; 272: 293-308.
48. Norol F, Vitrat N, Cramer E, Guichard J, Burstein SA, Vainchenker W et al. Effects of cytokines on platelet production from blood and marrow CD34\+ cells. Blood 1998; 91: 830-843.
49. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-553.
50. Koprinarova M, Botev P, Russev G. Histone deacetylase inhibitor sodium butyrate enhances cellular radiosensitivity by inhibiting both DNA nonhomologous end joining and homologous recombination. DNA Repair (Amst) 2011; 10: 970-977.